The Board of Directors approved the consolidated
financial statements for the 2nd quarter, 2022
Date of events
2022/08/05
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/05
2.Date of the audit committee approved:2022/08/05
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):2,205,174
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):779,522
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):169,306
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):179,715
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):142,110
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):99,277
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):1.17
11.Total assets end of the period (thousand NTD):4,219,324
12.Total liabilities end of the period
(thousand NTD):2,376,216
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,467,025
14.Any other matters that need to be specified:None.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Rossmax International Ltd. published this content on 05 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2022 08:20:02 UTC.
ROSSMAX INTERNATIONAL LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and retailing of medical devices. The Company's main products include digital sphygmomanometers, respiratory therapy products, temperature series products and blood oxygen meters. The Company distributes its products in domestic market and to overseas markets, including Europe, the Americas and others.